Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm. Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and ...

Yes, say the authors of a new study, which found that a mere 5% of routine follow-up visits among patients with diffuse large B-cell lymphoma (DLBCL) in remission resulted in detection of relapse.

These are the areas with the most intense standardized uptake values, which correlate with the most aggressive histology ... undergo transformation to DLBCL. 1 Histologic transformation of ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in relapsed/refractory Diffuse Large B-Cell Lymphoma, or r/r DLBCL.